SCHEMBL1137564

SCHEMBL1137564

O=C(O)COc1cccc2[nH]ccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.58
ALDH1A1 P00352 2/20 0.58
HPGD P15428 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
MCL1 Q07820 1/20 0.54
HTR1A P08908 8/20 0.52
DRD4 P21917 2/20 0.52
DRD3 P35462 2/20 0.52
DRD2 P14416 1/20 0.52
ROCK2 O75116 1/20 0.52
TNKS O95271 1/20 0.52
PARP1 P09874 1/20 0.52
ROCK1 Q13464 1/20 0.52
PARP14 Q460N5 1/20 0.52
PARP10 Q53GL7 1/20 0.52
PARP2 Q9UGN5 1/20 0.52
PARP3 Q9Y6F1 1/20 0.52
HTR1B P28222 2/20 0.51
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4217466 0.87 HTR1A (0.50) KDM4EALDH1A1HPGDTDP1MCL1
SCHEMBL1137563 0.84 HTR1B (0.53) KDM4EALDH1A1MCL1HTR1ADRD4
SCHEMBL3873208 0.83 HTR1A (0.56) KDM4EALDH1A1MCL1HTR1ADRD4
SCHEMBL15252019 0.82 F9 (0.49) KDM4EALDH1A1MCL1HTR1ADRD4
SCHEMBL11293879 0.80 HTR1A (0.60) KDM4EALDH1A1HTR1ADRD4DRD3
SCHEMBL2312464 0.79 RHEB (0.49) KDM4EALDH1A1MCL1HTR1ADRD4
SCHEMBL1137964 0.79 PTGER3 (0.56) MCL1DRD4DRD3DRD2ROCK2
SCHEMBL27533778 0.78 SLC22A6 (0.58) KDM4EALDH1A1HPGDTDP1LMNA
SCHEMBL12720773 0.77 HTR1B (0.55) KDM4EALDH1A1HTR1ADRD4DRD3
SCHEMBL6481749 0.77 HTR1B (0.55) KDM4EALDH1A1HTR1ADRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2766344-B1 EP1 RECEPTOR LIGANDS ESTEVE LABOR DR (ES) 2017-05-03 EP disclosed
US-9518015-B2 EP1 receptor ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2016-12-13 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20140323475-A1 EP1 RECEPTOR LIGANDS ESTEVE PHARMACEUTICALS, S.A. (ES) 2014-10-30 US disclosed
EP-2766344-A1 EP1 RECEPTOR LIGANDS Laboratorios Del. Dr. Esteve, S.A. (ES) 2014-08-20 EP disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2013037960-A1 EP1 RECEPTOR LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-03-21 WO disclosed
EP-2570125-A1 Ep1 receptor ligands Almirall, S.A. (ES) 2013-03-20 EP disclosed
EP-1812388-B1 SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE DECODE GENETICS EHF (IS) 2011-02-23 EP disclosed
US-20100096252-A1 PHOTOLABILE DINITROINDOLINYL BASED COMPOUNDS PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF (US) 2010-04-22 US disclosed
US-20090291948-A1 SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE DECODE GENETICS EHF (IS) 2009-11-26 US disclosed
WO-2008094922-A1 PHOTOLABILE DINITROINDOLINYL BASED COMPOUNDS PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) 2008-08-07 WO disclosed
EP-1812388-A1 SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE Decode Genetics (US) 2007-08-01 EP disclosed
WO-2006044000-A1 SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE DECODE GENETICS (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323475-A1 EP1 RECEPTOR LIGANDS PTGER1, PTGER2, PTGIR KDM4E 3864/4885ALDH1A1 654/4885HPGD 280/4885
US-20090291948-A1 SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE PTGIS, PTGIR, PTGS2 KDM4E 3447/4885ALDH1A1 903/4885HPGD 36/4885
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G KDM4E 1537/4885ALDH1A1 2071/4885HPGD 967/4885
US-20100096252-A1 PHOTOLABILE DINITROINDOLINYL BASED COMPOUNDS AANAT, TPH2, HTR3C KDM4E 1357/4885ALDH1A1 929/4885HPGD 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.